title: Dual regulation of δ-opioid receptor function by arachidonic acid metabolites in rat peripheral sensory neurons.
abstract: The regulation of opioid receptor system function in peripheral sensory neurons is not well understood. Opioid agonist efficacy to inhibit nociceptor function and to promote antinociception is generally weak under basal conditions and frequently no response occurs. However, in response to a cyclooxygenase-dependent metabolite of arachidonic acid (AA) after exposure to inflammatory mediators, such as bradykinin (BK) or exogenous AA, peripheral opioid receptor systems become much more responsive to opioid agonists. In this study, we examined the time course for the induction and maintenance of functional competence of the δ-opioid receptor (DOR) system in adult rat nociceptors in culture and in vivo. We found that the responsive state of DOR after pretreatment with BK or exogenous AA is transient (30-60 minutes) and persists for 15-30 minutes after a 15-minute exposure of nociceptors to BK or AA. Interestingly, whereas functional competence of the DOR system could be reinduced with a second application of BK 60 minutes after the first, responsiveness of the DOR system could not be reinduced after an initial exposure to AA. This nonresponsive state of DOR after exogenous AA was mediated by a lipoxygenase (LOX)-dependent metabolite of AA. Intraplantar carrageenan also produced transient DOR functional competence and responsiveness was also reinduced by inhibition of LOX. Thus, the DOR system expressed by peripheral sensory neurons is under dual regulation by cyclooxygenase- and LOX-dependent metabolites of AA.
authors: Department of Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, Texas.
authors: Laura C
authors: LC
authors: Sullivan
authors: Department of Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, Texas.
authors: Kelly A
authors: KA
authors: Berg
authors: Department of Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, Texas clarkew@uthscsa.edu.
authors: William P
authors: WP
authors: Clarke
mesh_terms: D000818:Animals; D016718:Arachidonic Acid / Q000378:metabolism* / Q000494:pharmacology; D001920:Bradykinin / Q000494:pharmacology; D002478:Cells, Cultured; D000242:Cyclic AMP / Q000378:metabolism; D051545:Cyclooxygenase 1 / Q000378:metabolism; D051546:Cyclooxygenase 2 / Q000378:metabolism; D015232:Dinoprostone / Q000494:pharmacology; D020881:Enkephalin, D-Penicillamine (2,5)- / Q000494:pharmacology; D006930:Hyperalgesia / Q000378:metabolism / Q000503:physiopathology; D008084:Lipoxygenase / Q000378:metabolism; D016859:Lipoxygenase Inhibitors / Q000494:pharmacology; D008297:Male; D017207:Rats, Sprague-Dawley; D017465:Receptors, Opioid, delta / Q000819:agonists / Q000378:metabolism*; D011984:Sensory Receptor Cells / Q000187:drug effects / Q000378:metabolism*; D012668:Trigeminal Ganglion / Q000166:cytology
chemical_list: D016859:Lipoxygenase Inhibitors; D017465:Receptors, Opioid, delta; D016718:Arachidonic Acid; D020881:Enkephalin, D-Penicillamine (2,5)-; D000242:Cyclic AMP; D008084:Lipoxygenase; D051545:Cyclooxygenase 1; D051546:Cyclooxygenase 2; D015232:Dinoprostone; D001920:Bradykinin
references: Pain. 2009 Feb;141(3):283-91
references: 19147290
references: Curr Opin Pharmacol. 2009 Feb;9(1):3-8
references: 19157985
references: Handb Exp Pharmacol. 2009;(194):495-518
references: 19655116
references: J Oral Maxillofac Surg. 2010 Mar;68(3):622-7
references: 20171481
references: Curr Med Res Opin. 2011 Feb;27(2):439-48
references: 21194392
references: J Pharmacol Exp Ther. 2011 Jul;338(1):92-9
references: 21487072
references: Mol Pharmacol. 2012 Feb;81(2):264-72
references: 22072818
references: Mol Pharmacol. 2012 Mar;81(3):375-83
references: 22144670
references: Pharmacol Rev. 2013;65(4):1257-317
references: 24076545
references: Clin Pharmacol Ther. 2001 Jul;70(1):66-73
references: 11452246
references: J Pain Symptom Manage. 2001 Apr;21(4):330-7
references: 11312048
references: Biomed Chromatogr. 2015 Jun;29(6):902-10
references: 25515821
references: Anesth Analg. 2001 Sep;93(3):761-70
references: 11524353
references: Eur J Pharmacol. 2001 Oct 19;429(1-3):79-91
references: 11698029
references: Proc Natl Acad Sci U S A. 2002 Jul 23;99(15):10150-5
references: 12097645
references: Nat Med. 2003 Aug;9(8):1003-8
references: 12894165
references: J Biol Chem. 1979 Oct 10;254(19):9772-9
references: 489567
references: Nature. 1980 Mar 27;284(5754):351-3
references: 6244504
references: Br J Pharmacol. 1985 Sep;86(1):55-62
references: 2996675
references: Biochem Pharmacol. 1987 Jul 15;36(14):2405-13
references: 3111482
references: Anesth Analg. 1987 Dec;66(12):1277-81
references: 2891323
references: Pain. 1988 Jan;32(1):77-88
references: 3340425
references: Pain. 1990 Oct;43(1):95-103
references: 2277720
references: Mol Pharmacol. 1997 Apr;51(4):666-73
references: 9106633
references: Nature. 1997 Dec 11;390(6660):611-4
references: 9403690
references: J Neurosci. 1999 Aug 1;19(15):6629-36
references: 10414991
references: Proc Soc Exp Biol Med. 1962 Dec;111:544-7
references: 14001233
references: Arch Intern Med. 2005 Jul 25;165(14):1574-80
references: 16043674
references: J Neurosci. 2005 Sep 28;25(39):8825-32
references: 16192372
references: Pain. 2006 Nov;125(1-2):114-24
references: 16781076
references: Reg Anesth Pain Med. 2006 Nov-Dec;31(6):506-13
references: 17138192
references: Neuroscience. 2007 Feb 9;144(3):889-97
references: 17157995
references: J Pharmacol Exp Ther. 2007 Jun;321(3):839-47
references: 17347322
references: Pain Physician. 2008 Mar;11(2 Suppl):S105-20
references: 18443635
references: Eur J Pharmacol. 2009 Jan 14;602(2-3):283-7
references: 19063879